SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance
Authors' conclusion
Whilst prescribing of SGLT2 inhibitors continues to rise in England, recent trends indicate an opportunity remains to increase uptake.
Study context
- Population
- People with T2D in England, Clinical Practise Research Data Link records, 1 September 2023 (18 months after NICE guideline update)
- Participants
- 587,826 people
- Exposure
- SGLT2i prescription uptake by cardiovascular disease (CVD) category
- Outcome
- Current prescription for an SGLT2i
- Follow-up
- 1 September 2023
Methodological detailslinked to hospital admissions, logistic regression
- Linked to hospital admissions
- Logistic regression
Main finding
As reported in the abstract
Current SGLT2i prescription
Observational data: associations, not effects.
Further findings
Uptake by comorbidity, age-stratified
- Uptake higher in people with more comorbidities
Adjusted associations of patient characteristics with uptake
- Uptake lower in people aged > 60, women, Black people and those in areas of higher deprivation
- Adjusted models
Original publication
SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance. Diabetes Obes Metab. Published 4 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →